Page last updated on April 15, 2025
Kairos Pharma, LTD. reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2025-04-15 17:30:06 EDT.
Filings
10-K filed on 2025-04-15
Kairos Pharma, LTD. filed a 10-K at 2025-04-15 17:30:06 EDT
Accession Number: 0001641172-25-004920
Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!
Item 1C. Cybersecurity.
ITEM 1C. CYBERSECURITY Risk Management and Strategy We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity , or availability of our information systems or any information residing therein. We conduct risk assessments at least annually to identify cybersecurity threats. These risk assessments include identifying reasonably foreseeable potential internal and external risks, the likelihood of occurrence and any potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, controls and other safeguards we have put in place to manage such risks. Our risk management process also encompasses cybersecurity risks associated with the use of our major third-party vendors and service providers. For additional information regarding whether any risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect our company, including our business strategy, results of operations, or financial condition, please refer to Item 1A “Risk Factors” in this Annual Report on Form 10-K , including the risk factors entitled “Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs,” and “Our proprietary information, or that of our customers, suppliers and business partners, may be lost or we may suffer security breaches.” Governance One of the key functions of our Board of Directors is informed oversight of our risk management process, including risks arising from cybersecurity threats. Our Board of Directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our Chief Financial Officer is primarily responsible for assessing and managing material risks from cybersecurity threats on a day to day basis.
Company Information
Name | Kairos Pharma, LTD. |
CIK | 0001962011 |
SIC Description | Pharmaceutical Preparations |
Ticker | KAPA - NYSE |
Website | |
Category | Emerging growth company |
Fiscal Year End | December 30 |